Recursion Pharmaceuticals RXRX
NASDAQ RXRX
$4.12 +0.05 (+1.23%)
At close: Oct 2, 2026 · 4:00 PM EDT

Recursion Pharmaceuticals (RXRX) Asset Writedowns and Impairment (2022 - 2025)

Updated

Recursion Pharmaceuticals' Asset Writedowns and Impairment was $5.96 million in FY2025, compared with $108,000 in FY2024.

Analysis

Recursion Pharmaceuticals (RXRX) Asset Writedowns and Impairment (2022 - 2025) Analysis & Trends

From FY2020 onward, Recursion Pharmaceuticals has reported Asset Writedowns and Impairment for 5 years.

  • Asset Writedowns and Impairment shows a five-year compound annual growth rate of 46.8% (FY2020 to FY2025).
  • The FY2025 figure marks the highest annual Asset Writedowns and Impairment in data going back to FY2020.
  • Per Business Quant data, Asset Writedowns and Impairment in earlier years was $108,000 in FY2024 (-90.9%), $1.19 million in FY2023 (-57.7%) and $2.81 million in FY2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Recursion Pharmaceuticals 2.20 Bn -402.71 Mn -3.82 Mn
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2025 5.96 Mn
Mar 31, 2024 108,000.00
Sep 30, 2023 19,000.00
Mar 31, 2023 1.17 Mn
Jun 30, 2022 2.81 Mn
API Access

Recursion Pharmaceuticals Asset Writedowns and Impairment API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=asset-writedowns-and-impairment&ticker=RXRX&period=max&api_key=YOUR_API_KEY